Dione Antibiotics, Inc. is an early-stage biopharmaceutical company uniquely positioned to develop a fundamentally new class of proprietary small molecule, non-traditional, direct acting antibiotics against a new drug target to treat drug-resistant 'superbug' bacterial infections.

​

Our Antibiotic Program has identified the first new drug target in over 40 years with small molecule compounds directed against it that have not been approved by the FDA nor EMA. Preliminary data show efficacy and safety against drug-resistant bacterial pathogens.